Premium
Therapeutic effects of growth hormone combined with low‐dose stanozolol on growth velocity and final height of girls with Turner syndrome
Author(s) -
Xiong Hui,
Chen HongShan,
Du MinLian,
Li YanHong,
Ma HuaMei,
Su Zhe,
Chen QiuLi
Publication year - 2015
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12785
Subject(s) - stanozolol , turner syndrome , endocrinology , medicine , growth hormone , turner's syndrome , growth velocity , hormone , anabolism
Summary Objective Turner syndrome ( TS ), which is characterized by short stature and gonadal dysfunction, is managed by pharmacotherapy. This study aimed to investigate the therapeutic effects of recombinant human growth hormone (rh GH ) combined with low‐dose stanozolol on the growth and final adult height ( FAH ) of girls with Turner syndrome ( TS ). Design Prospective study. Patients A total of 44 girls with TS were treated with rh GH (47·6–52·4 μg/kg/day) and low‐dose stanozolol (20–35 μg/kg/day), starting at a mean age of 12·65 ± 1·99 year. The control group consisted of 22 girls with TS , who did not receive treatment. Measurements Subjects’ growth velocity ( GV ) was investigated. Height standard deviation score (Ht SDS ) was calculated relative to healthy Chinese girls (Ht SDS N or ) as well as untreated Chinese girls with TS (Ht SDS TS ). Post‐treatment follow‐up was performed until the subjects achieved FAH or near FAH . Results FAH was significantly higher in subjects receiving treatment compared to the untreated controls (151·42 vs 137·75 cm, P < 0·001). GV was significantly higher in the first to fourth years of treatment compared to baseline values ( P < 0·001); it was significantly lower in the second to fourth years of treatment compared to the first year ( P < 0·001). Conclusions In girls with TS , 9–12 years of age, rh GH combined with low‐dose stanozolol may effectively increase growth. At least a 2‐year course of this treatment may effectively improve FAH with proper delay of oestrogen‐induced development.